Biotechnology News

Celularity regains Nasdaq reporting compliance and begins a finance department overhaul to strengthen accountability and ensure timely financial reporting.

MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

CLEARWATER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the...

Phase 3 trial alignment paves path toward New Drug Application and potential approval of RGT-61159, an oral small molecule targeting the MYB oncogenePrior preliminary data in patients treated at or...

GOLDEN, Colo., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ignite Proteomics, Inc. (“Ignite” or the “Company”), a precision oncology company focused on functional proteomics, today announced it is...

4Tissue raises €7 million in Series A funding and appoints Stéphanie Dupont as CEO to advance its regenerative medicine technology and clinical development

Total of 618 patients randomized Topline 12-week data expected in Q1 2027 MILAN and MORRISTOWN, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA:...

SOMERVILLE, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc. (Nasdaq: GENB) (“Generate”) today announced that members of its management team will participate in presentations at...

Published data validates ZIP12-mediated zinc signaling as a novel driver of pulmonary vascular remodeling and supports a differentiated therapeutic approach targeting underlying disease biology Phase...

MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, will host a...